Medicare AdvantageDocumentationMedium impact
MA08.093q, Chimeric Antigen Receptor (CART) Therapy: Yescarta Tecartus, Breyanzi, Kymriah and Aucatzyl
Independence Blue Cross·Oncology, Hematology·Medical Policy
Effective date
Feb 9, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.093q updates medical necessity criteria, medical coding guidelines, and general informational content for Chimeric Antigen Receptor (CAR-T) Therapy treatments including Yescarta, Tecartus, Breyanzi, Kymriah, and Aucatzyl. This recent policy (1 month old) requires billing teams to review and align coding and prior authorization procedures with the updated medical necessity standards for CAR-T cell therapies.
Action Required
By February 9, 2026: Billing team must review the full policy text at the provided source URL and update internal documentation regarding medical necessity criteria for CAR-T therapies (Yescarta, Tecartus, Breyanzi, Kymriah, Aucatzyl). Coordinate with providers and prior authorization staff to ensure all CAR-T therapy claims align with the updated medical necessity standards. Update any internal billing guidelines, prior authorization workflows, and claim submission procedures to reflect changes. Verify that all supporting documentation requirements are met before claim submission to avoid denials.